BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh SM, Wijeysundera HC. Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation. Curr Cardiol Rep 2015;17:61. [PMID: 26081245 DOI: 10.1007/s11886-015-0618-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Kamuren Z, Kigen G, Keter A, Maritim A. Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings. BMC Health Serv Res 2018;18:723. [PMID: 30231891 DOI: 10.1186/s12913-018-3537-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Hendriks T, McGregor S, Rakesh S, Robinson J, Ho KM, Baker R. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study. PLoS One 2020;15:e0234048. [PMID: 32497116 DOI: 10.1371/journal.pone.0234048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Vallakati A, Lewis WR. Underuse of anticoagulation in patients with atrial fibrillation. Postgrad Med 2016;128:191-200. [PMID: 26666288 DOI: 10.1080/00325481.2016.1132939] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
4 Paravattil B, Elewa H. Approaches to Direct Oral Anticoagulant Selection in Practice. J Cardiovasc Pharmacol Ther 2018;:1074248418793137. [PMID: 30092658 DOI: 10.1177/1074248418793137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Al Mukdad M, Al-Badriyeh D, Elewa HF. Cost-effectiveness Evaluations Among the Direct Oral Anticoagulants for the Prevention and Treatment of Venous Thromboembolism: Systematic Review. Clin Appl Thromb Hemost 2019;25:1076029619849103. [PMID: 31088296 DOI: 10.1177/1076029619849103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Chi NF, Wang Y, Chien LN, Chien SC, Ko Y. Health Care Costs and Utilization of Dabigatran Compared With Warfarin for Secondary Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Retrospective Population Study. Med Care 2018;56:410-5. [PMID: 29578954 DOI: 10.1097/MLR.0000000000000901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Athanasakis K, Karampli E, Tsounis D, Bilitou A, Kyriopoulos J. Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting. Clin Drug Investig 2015;35:693-705. [PMID: 26385756 DOI: 10.1007/s40261-015-0321-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Peacock WF, Rafique Z, Singer AJ. Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians. Emerg Med Int 2016;2016:1781684. [PMID: 27293895 DOI: 10.1155/2016/1781684] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
9 Bobade RA, Helmers RA, Jaeger TM, Odell LJ, Haas DA, Kaplan RS. Time-driven activity-based cost analysis for outpatient anticoagulation therapy: direct costs in a primary care setting with optimal performance. J Med Econ 2019;22:471-7. [PMID: 30744455 DOI: 10.1080/13696998.2019.1582058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]